Table 1.
Selected meta-analysis studies demonstrating the increased risk of clinical manifestations in antiphospholipid antibody (aPL) -positive systemic lupus erythematosus (SLE) patients compared with that in aPL-negative SLE patients
| Manifestations | Increased risk [OR (95% CI)] | |||
|---|---|---|---|---|
|
|
||||
| LA | aCL | aβ2GPI | aPL | |
| Venous thromboembolism (51) | 5.6 (3.8–8.2) | 2.1 (1.5–3.1) | N/A | N/A |
| Pregnancy morbidity (56) | N/A | N/A | N/A | Increaseda |
| Valvular disease (71) | 5.8 (2.9–11.8) | 5.6 (3.5–8.9) | N/A | 3.1 (2.3–4.2) |
| Pulmonary hypertension (77) | 2.4 (1.5–3.9) | 3.1 (2.0–4.8) | NS | 2.5 (1.8–3.3) |
| Livedo reticularis (83) | 4.7 (2.4–9.2) | 3.3 (2.2–4.9) | 3.4 (1.5–7.5) | 3.4 (2.5–4.6) |
| Thrombocytopenia (85) | 3.4 (2.6–4.5) | 2.0 (1.6–2.4) | 2.7 (1.4–5.0) | 2.7 (2.4–3.2) |
| Hemolytic anemia (91) | 4.6 (2.6–8.0) | 2.9 (2.2–3.9) | 4.0 (1.5–10.7) | 3.2 (2.4–4.3) |
| Renal impairment (96) | 2.8 (1.1–7.6) | 3.1 (1.1–9.0) | NS | 2.9 (1.9–4.3) |
aCL: anticardiolipin antibodies, aβ2GPI: anti-β2-glycoprotein-I antibodies, CI: confidence interval, LA: lupus anticoagulant, NS: not significant, OR: odds ratio; aPL: antiphospholipid antibodies
a
Odds Ratio is not available for this study, which is based on lupus nephritis patients